MTOR and tuberous sclerosis: In clinical studies, topical sirolimus decreases angiofibromas, hypomelanotic macules, or cephalic plaques, and is well tolerated by children.12, 13, 14 Therefore, TSC skin lesions are not only important for the diagnosis of the disease but can be effectively treated by targeting mTOR hyperactivation.